• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于生理药代动力学模型的人用局部阿托品眼部暴露预测

An Ocular Exposure Prediction for Topical Atropine in Human Using Physiologically Based Pharmacokinetic Modeling.

作者信息

Zheng Aole, Han Tian, Bu Fengjiao, He Qingfeng, Shang Jianmin, Ho Paul Chi Lui, Xiang Xiaoqiang, Zhou Xingtao, Huang Taomin

机构信息

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, 201203, China.

Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.

出版信息

AAPS J. 2025 May 2;27(4):89. doi: 10.1208/s12248-025-01052-7.

DOI:10.1208/s12248-025-01052-7
PMID:40316760
Abstract

Developing a mathematical model to predict the distribution and bioavailability of atropine in human eyes is an insight approach for clinical practice. This study aims to develop a human ocular physiologically based pharmacokinetic (PBPK) modeling for the ophthalmic drug atropine and explore possible mechanisms by which atropine reduces myopia progression in children. The Ocular Compartment Absorption and Transit (OCAT™) model was employed to describe the ocular distribution of atropine following administration at different dosages in both rabbits and humans. The PBPK model enables the extrapolation of pharmacokinetic characteristics among different species depending on theirphysiology and anatomy. The developed and validated OCAT-PBPK model demonstrated good agreement with observed data from rabbit ocular tissues and human aqueous humor. Fifty-eight percent of simulations fell within the standard deviation range of experimental data. The extrapolated human PBPK model for accurately predicted the ocular exposure and distribution following the administration of low-concentration atropine. This study confirms the performance of the ocular PBPK model in predicting ocular pharmacokinetic behavior among different species. Model's predictions indicate that atropine shows significant potential to penetrate the posterior eye segment, providing underlying insights into its mechanisms of action in the eye.

摘要

建立一个数学模型来预测阿托品在人眼中的分布和生物利用度是一种对临床实践有深刻见解的方法。本研究旨在建立一种基于人体眼部生理的药代动力学(PBPK)模型,用于眼科药物阿托品,并探索阿托品减缓儿童近视进展的可能机制。采用眼室吸收和转运(OCAT™)模型来描述不同剂量给药后阿托品在兔和人眼中的分布。PBPK模型能够根据不同物种的生理和解剖结构推断其药代动力学特征。所建立并验证的OCAT-PBPK模型与兔眼组织和人房水的观察数据显示出良好的一致性。58%的模拟结果落在实验数据的标准差范围内。外推得到的人体PBPK模型准确预测了低浓度阿托品给药后的眼部暴露和分布情况。本研究证实了眼部PBPK模型在预测不同物种眼部药代动力学行为方面的性能。模型预测表明,阿托品具有穿透眼后节的显著潜力,为其在眼部的作用机制提供了潜在的见解。

相似文献

1
An Ocular Exposure Prediction for Topical Atropine in Human Using Physiologically Based Pharmacokinetic Modeling.基于生理药代动力学模型的人用局部阿托品眼部暴露预测
AAPS J. 2025 May 2;27(4):89. doi: 10.1208/s12248-025-01052-7.
2
Physiologically Based Pharmacokinetic Modeling and Clinical Extrapolation for Topical Application of Pilocarpine on Eyelids: A Comprehensive Study.基于生理学的眼部应用毛果芸香碱的药代动力学模型构建和临床外推:一项全面研究。
J Pharm Sci. 2024 Sep;113(9):2861-2870. doi: 10.1016/j.xphs.2024.06.004. Epub 2024 Jun 8.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Topical review: Potential mechanisms of atropine for myopia control.专题综述:阿托品控制近视的潜在机制
Optom Vis Sci. 2025 May 1;102(5):260-270. doi: 10.1097/OPX.0000000000002249. Epub 2025 Mar 28.
5
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
6
Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.经口丁丙诺啡生理药代动力学模型的建立与验证:考虑到非线 性生物利用度,该模型适用于健康成年志愿者
Drug Metab Dispos. 2024 Jul 16;52(8):785-796. doi: 10.1124/dmd.124.001643.
7
Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study.阿托品治疗儿童近视控制的长期评估研究。
JAMA Ophthalmol. 2024 Jan 1;142(1):15-23. doi: 10.1001/jamaophthalmol.2023.5467.
8
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
9
A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide.一种基于生理药代动力学(PBPK)模型的自下而上方法用于突变型和野生型柯利犬:以洛哌丁胺为例的案例研究
AAPS J. 2025 Jun 2;27(4):101. doi: 10.1208/s12248-025-01061-6.
10
Microfluidic blood-milk barrier and physiologically based pharmacokinetic model to predict lofexidine secretion into breast milk.微流控血乳屏障及基于生理学的药代动力学模型用于预测洛非西定向母乳中的分泌情况。
J Pharm Sci. 2025 Jun;114(6):103767. doi: 10.1016/j.xphs.2025.103767. Epub 2025 Mar 19.

本文引用的文献

1
Clinical Ocular Exposure Extrapolation for a Complex Ophthalmic Suspension Using Physiologically Based Pharmacokinetic Modeling and Simulation.使用基于生理药代动力学建模与模拟对复杂眼科混悬剂进行临床眼部暴露外推
Pharmaceutics. 2024 Jul 9;16(7):914. doi: 10.3390/pharmaceutics16070914.
2
Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population.儿童阿托品近视研究:欧洲人群中每日使用 0.01%阿托品两年的结果。
Acta Ophthalmol. 2024 May;102(3):e245-e256. doi: 10.1111/aos.15761. Epub 2023 Sep 11.
3
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies.
用于单克隆抗体眼部处置的基于生理学的翻译药代动力学模型。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):493-508. doi: 10.1007/s10928-023-09881-9. Epub 2023 Aug 9.
4
Atropine, 0.01%, for Myopia Control.0.01%阿托品用于控制近视。
JAMA Ophthalmol. 2023 Aug 1;141(8):766-767. doi: 10.1001/jamaophthalmol.2023.3076.
5
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial.低浓度 0.01%阿托品滴眼液与安慰剂治疗近视的随机临床试验。
JAMA Ophthalmol. 2023 Aug 1;141(8):756-765. doi: 10.1001/jamaophthalmol.2023.2855.
6
Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.低浓度阿托品滴眼液与安慰剂对儿童近视发生率的影响:LAMP2 随机临床试验。
JAMA. 2023 Feb 14;329(6):472-481. doi: 10.1001/jama.2022.24162.
7
Quantitative systems pharmacology of the eye: Tools and data for ocular QSP.定量系统药理学在眼部的应用:眼部 QSP 的工具和数据。
CPT Pharmacometrics Syst Pharmacol. 2023 Mar;12(3):288-299. doi: 10.1002/psp4.12918. Epub 2023 Jan 27.
8
Mendelian Randomization Implicates Bidirectional Association between Myopia and Primary Open-Angle Glaucoma or Intraocular Pressure.孟德尔随机化提示近视与原发性开角型青光眼或眼压之间存在双向关联。
Ophthalmology. 2023 Apr;130(4):394-403. doi: 10.1016/j.ophtha.2022.11.030. Epub 2022 Dec 6.
9
Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation.临床眼部暴露外推法在眼科溶液中的应用:基于 PBPK 建模与模拟。
Pharm Res. 2023 Feb;40(2):431-447. doi: 10.1007/s11095-022-03390-z. Epub 2022 Sep 23.
10
Stable Atropine Loaded Film As a Potential Ocular Delivery System For Treatment Of Myopia.稳定载阿托品膜作为一种治疗近视的潜在眼部给药系统。
Pharm Res. 2021 Nov;38(11):1931-1946. doi: 10.1007/s11095-021-03135-4. Epub 2021 Nov 12.